Intuitive Surgical Inc. (ISRG) Stock Analysis
BriMind AI Score
ProprietaryScore based on historical price CAGR, revenue growth, analyst upside, and valuation factors. Updated daily.
BriMind 1-Year Price Target
BriMind AI combines DCF, momentum, and analyst consensus to project a 12-month price target.
About Intuitive Surgical Inc.
Intuitive Surgical is the undisputed leader in robotic-assisted surgery, with its da Vinci surgical system installed in 9,000+ hospitals worldwide. The company's robots assist surgeons in performing minimally invasive procedures across urology (prostatectomy), gynecology (hysterectomy), general surgery (hernia repair, cholecystectomy), and thoracic surgery. Intuitive launched the next-generation da Vinci 5 system in 2024, its most significant platform upgrade in a decade.
How Intuitive Makes Money
Intuitive earns from a razor-and-blade model: system placements (~17% of revenue — da Vinci robots cost $1-2.5M each), instruments and accessories (~55% — single-use instruments consumed per procedure, $700-3,500 per procedure), and services (~28% — maintenance contracts and training). The recurring instruments and services revenue is the key to the business — once a hospital buys a robot, it generates decades of consumable revenue.
Intuitive Revenue & Profitability Breakdown
This chart shows how Intuitive's revenue flows through to profit. Each row deducts a layer of costs: first the direct cost of making products/services (Cost of Revenue), then operating expenses like marketing and R&D, then taxes. What remains at the bottom is net income — the actual profit shareholders own. High gross and net margins indicate a business with strong pricing power and efficiency.
Key Financial Metrics
A snapshot of the company's valuation, growth, profitability, and financial health. Key things to look at: P/E ratio measures how much you pay for $1 of earnings (lower = cheaper, but fast-growing companies command higher P/E); Free Cash Flow is the cash left after running the business — companies with strong FCF can buy back shares, pay dividends, or invest; Debt/Equity shows how leveraged the company is (high debt can be risky); Return on Equity tells you how efficiently the company generates profit from shareholders' money.
Wall Street Analyst Consensus
Professional analysts at investment banks set 12-month price targets after researching the company's earnings, competitive position, and industry trends. Strong Buy / Buy means the majority expect meaningful upside. Hold means analysts see fair value near the current price — not a sell signal, but limited near-term upside expected. The mean target is the average of all analyst price targets; the range shows where the most optimistic and most cautious analysts stand.
Intrinsic Value Estimates for ISRG
Intrinsic value is what a stock is truly worth based on the company's fundamentals — independent of what the market currently prices it at. We use multiple models because no single formula is perfect: each captures different aspects of a business. If multiple models agree the stock is undervalued, that convergence is a stronger signal. A stock trading well below its intrinsic value may be a bargain; one far above may carry more risk.
⚠️ Intrinsic value estimates use simplified models (Graham, DCF, P/E) and conservative assumptions. They should be used as one input among many — not as sole buy/sell guidance. For advanced analysis, see the full platform.
ISRG Investment Case: Bull vs Bear
Every investment has two sides. The bull case outlines the key reasons the stock could outperform — competitive advantages, growth catalysts, and market tailwinds. The bear case highlights the most significant risks that could cause the investment to underperform. Good investors read both sides carefully before deciding. A strong bull case with manageable bear risks typically makes for a more compelling investment.
Bull Case (Reasons to Buy)
- da Vinci 5 is a generational upgrade — force feedback, AI-powered insights, and improved ergonomics should accelerate adoption and expand into new procedure types.
- Only 3-5% of addressable procedures are performed robotically — the penetration runway is enormous, particularly in general surgery and international markets.
- Installed base of 9,000+ systems generates $6B+ in recurring instruments and services revenue — a durable, growing annuity stream.
- First-mover advantage with 25+ years of surgeon training creates switching costs — surgeons trained on da Vinci are reluctant to switch to competing platforms.
Bear Case (Key Risks)
- Valuation is extreme — at 60-70x forward P/E, Intuitive is priced for flawless execution over many years.
- Competition is intensifying — Medtronic (Hugo), J&J (Ottava), and Stryker are developing surgical robots that could erode Intuitive's monopoly.
- da Vinci 5 transition may cannibalize da Vinci Xi placements in the near term as hospitals wait for the new system.
- Hospital capital budgets are pressured — expensive robotic systems ($1-2.5M) face scrutiny when hospital margins are thin.
What to Watch: ISRG Key Metrics
ISRG Stock — Frequently Asked Questions
Compare ISRG with Peers
Unlock the Full ISRG Analysis
Interactive price charts, real-time AI signals, advanced DCF models, portfolio tracking, earnings analysis, and side-by-side peer comparisons. Start your 21-day free trial — no credit card required.